Central Pacific Bank Trust Division Acquires Shares of 1,145 Madrigal Pharmaceuticals, Inc. $MDGL

Central Pacific Bank Trust Division acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,145 shares of the biopharmaceutical company’s stock, valued at approximately $615,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hsbc Holdings PLC acquired a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at about $309,000. Qube Research & Technologies Ltd acquired a new stake in Madrigal Pharmaceuticals in the 2nd quarter worth about $1,163,000. Sei Investments Co. raised its stake in Madrigal Pharmaceuticals by 73.6% in the 2nd quarter. Sei Investments Co. now owns 17,542 shares of the biopharmaceutical company’s stock worth $5,309,000 after purchasing an additional 7,438 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Madrigal Pharmaceuticals by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company’s stock valued at $7,087,000 after purchasing an additional 471 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at about $418,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MDGL. Barclays lowered their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a report on Monday. Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Bank of America lowered their price objective on Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. Finally, UBS Group reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Fifteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $689.93.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ:MDGL opened at $514.12 on Thursday. The firm has a 50 day moving average of $515.17 and a 200-day moving average of $499.03. The stock has a market capitalization of $11.88 billion, a PE ratio of -39.89 and a beta of -1.01. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65. Madrigal Pharmaceuticals, Inc. has a 12 month low of $331.00 and a 12 month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.68) by $0.69. The business had revenue of $364.25 million for the quarter, compared to analyst estimates of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The firm’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.90) EPS. On average, equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.03 EPS for the current fiscal year.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Wolfe Research upgraded MDGL to “Outperform” from “Peer Perform” and set a $605 price target. The target implies approximately 17.7% potential upside from the referenced price, signaling increased confidence in Madrigal’s commercial outlook and supporting investor sentiment. Benzinga report
• Positive Sentiment: HC Wainwright raised its 2026 earnings forecasts. The firm now expects third-quarter 2026 EPS of $(0.10), versus $(1.05) previously, and fourth-quarter EPS of $0.85, versus $0.18. Its full-year 2026 forecast also improved to $(4.47) from $(7.07), while maintaining a “Buy” rating. These revisions suggest analysts expect Madrigal’s business to approach profitability faster than previously anticipated. MarketBeat analyst estimates
• Positive Sentiment: A recent analysis described the launch environment for semaglutide as manageable and Madrigal’s pipeline strategy as disciplined. The view that the company can navigate competition from semaglutide while concentrating resources on its core opportunities may be reassuring to investors evaluating long-term growth and execution risk. Seeking Alpha analysis
• Neutral Sentiment: HC Wainwright continues to project a transition from losses in 2026 to positive EPS beginning in 2027, but its estimates remain dependent on successful commercialization and future execution.
• Negative Sentiment: HC Wainwright reduced its longer-term EPS estimates. Forecasts were lowered for 2027 through 2030, including 2027 EPS to $8.32 from $11.78 and 2030 EPS to $77.98 from $93.68. Although the firm remains bullish, the cuts temper the valuation upside implied by the revised near-term estimates.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,682 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director owned 22,015 shares of the company’s stock, valued at approximately $11,347,411.60. This trade represents a 20.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the transaction, the insider directly owned 10,033 shares of the company’s stock, valued at $4,973,759.42. This trade represents a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,568 shares of company stock valued at $3,880,711 over the last 90 days. Corporate insiders own 17.60% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.